Pharsight

Velcade generic

Velcade is an anti-cancer drug owned by Takeda Pharms Usa. It contains the active ingredient bortezomib and is available in injectable;intravenous, subcutaneous dosage forms. The drug was first authorised for market use on 13 May, 2003.

When will Velcade generic be available?

The generic version of Velcade may become available after 25 July, 2022. This is when the last of its 4 drug patents is set to expire. The two key patents are US6713446*PED and US6958319*PED, both titled 'Formulation of boronic acid compounds' and both expiring on 25 July, 2022.

Velcade uses

Velcade is primarily used for the treatment of multiple myeloma and mantle cell lymphoma, two types of cancer. Its active ingredient, bortezomib, works by disrupting the breaking down of proteins in the cells that are quick to divide, like cancer cells. This increases the number of unwanted cells in the body, leading to their death. As a result, the growth of cancer cells is stopped, which slows the progress of the disease.

Velcade patent expiration

Velcade, owned by Takeda Pharms Usa, holds 4 drug patents, all of which have now expired. The latest patency, US6958319*PED, will expire on 25 July, 2022, potentially paving the way for the release of Velcade generics. Below are the details of the patent:

EPO Oppostions filed on Velcade

Velcade dosage

Want to ask something?